IP Library › Granted Patent US 12,342,828
Granted Patent B2
US 12,342,828 · App. 17/217,967 · Granted Jul 1, 2025

Repellant formulation and method

Inventors: Vadim Mitlitski (Demarest, NJ); Richard Robert Tenore (Narrowsburg, NY); Erica Rattigan Tyree (Amherst, VA)
Assignee: Insight Pharmaceuticals Corporation
A01N65/22A01N25/04A01N65/06A01N65/08A01N65/24A01N65/28A01N65/42A01N65/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,342,828
App. No.
17/217,967
Granted
Jul 1, 2025
Kind
B2
Abstract

A formulation for repelling insects and arthropods comprises about 0.5% by weight to about 4.0% by weight of an active ingredient and an emulsifier. The active ingredient includes a mixture of one or more natural essential oils. A method for making the repellant formulation comprises forming an oil-in-water emulsion by mixing one or more of the natural essential oils into an aqueous solution including an emulsifier, homogenizing the oil-in-water emulsion, and adding a buffer to the emulsion for maintaining a pH of the emulsion at above about 7.5. The repellant formulation is used by applying an effective amount of the repellant formulation onto the skin or fur of a mammal, clothing or other surface.

Claims (19)

1. A formulation for repelling insects and arthropods, the repellant formulation consisting essentially of:

about 0.5% by weight to about 4.0% by weight of an active ingredient, the active ingredient including a mixture of one or more natural essential oils; and

an emulsifier comprising a mixture of two parts fatty acid soap and eight parts mono and di-glycerides, wherein the mixed emulsifier has a hydrophilic-lipophilic balance (HLB) between about 5 and about 7,

wherein fine droplets of the active ingredient are freely dispersed within the emulsifier forming an emulsion.

2. The repellant formulation as recited in claim 1 , wherein the active ingredient comprises

up to about 50% by weight of citronella oil, and

about 50% by weight of a second essential oil.

3. The repellant formulation as recited in claim 2 , wherein the second essential oil is selected from cedarwood oil, cinnamon oil, clove oil, cornmint oil, eucalyptus oil, garlic oil, geranium oil, lemongrass oil, peppermint oil, rosemary oil, spearmint oil, thyme oil or combinations thereof.

4. The repellant formulation as recited in claim 1 , wherein the one or more essential oils include isolates thereof, derivatives thereof or synthetic equivalents thereof.

5. The repellant formulation as recited in claim 1 , wherein the emulsifier is provided at a ratio of about 1:1 emulsifier to the one or more essential oils.

6. The repellant formulation as recited in claim 1 , wherein the soap is selected from potassium soap, sodium soap, ammonium soap, monovalent salts of natural fatty acids or combinations thereof.

7. The repellant formulation as recited in claim 1 , wherein the fatty acid comprises a vegetable fat.

8. The repellant formulation as recited in claim 1 , wherein the fatty acid comprises an animal fat.

9. The repellant formulation as recited in claim 1 , wherein the fatty acid soap comprises potassium laurate.

10. The repellant formulation as recited in claim 9 , wherein the potassium laurate is selected from purified or whole cut coconut fatty acid, palm kernel fatty acids or mixtures thereof.

11. The repellant formulation as recited in claim 1 , wherein the mono and di glycerides comprise a vegetable fat.

12. The repellant formulation as recited in claim 1 , wherein the mono and di glycerides comprise an animal fat.

13. The repellant formulation as recited in claim 1 , wherein the mono and di glycerides comprise glyceryl monooleate.

14. The repellant formulation as recited in claim 1 , wherein the repellant formulation has a pH of about 8 to about 9.

Assignments (2)
PATENT SECURITY AGREEMENT (ABL) Recorded Apr 25, 2024
From: DENTEK ORAL CARE, INC.; INSIGHT PHARMACEUTICALS CORPORATION; MEDTECH PRODUCTS INC.
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 067239/0063 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2022
From: MITLITSKI, VADIM; TENORE, RICHARD ROBERT; TYREE, ERICA RATTIGAN
To: INSIGHT PHARMACEUTICALS CORPORATION
Reel/Frame 059756/0238 →
Continuity (2)
Provisional Application 63078059 · Sep 14, 2020
Related Publication 20220079166A1 · Mar 17, 2022
References Cited (142)
US 4238499A · Lover · 1980 [cited by applicant]
US 4356180A · McGovern · 1982 [cited by examiner]
US 5093124A · Kulenkampff · 1992 [cited by applicant]
US 5292504A · Cardin · 1994 [cited by applicant]
US 5518736A · Magdassi et al. · 1996 [cited by applicant]
US 5610130A · Thomas et al. · 1997 [cited by applicant]
US 5614558A · James · 1997 [cited by examiner]
US 5696158A · Oliver · 1997 [cited by applicant]
US 5736584A · Kunkel · 1998 [cited by examiner]
US 5885600A · Blum et al. · 1999 [cited by applicant]
US 5902595A · Burklow et al. · 1999 [cited by applicant]
US 6063771A · Snyder · 2000 [cited by applicant]
US 6147091A · Kruger et al. · 2000 [cited by applicant]
US 6207179B1 · Mihalik · 2001 [cited by applicant]
US 6277415B1 · Levin · 2001 [cited by applicant]
US 6538027B2 · Manker et al. · 2003 [cited by applicant]
US 6544530B1 · Friedman · 2003 [cited by applicant]
US 6607716B1 · Smith et al. · 2003 [cited by applicant]
US 6663876B2 · Campbell et al. · 2003 [cited by applicant]
US 6685969B2 · Van Scoik et al. · 2004 [cited by applicant]
US 6727228B2 · Janssen et al. · 2004 [cited by applicant]
US 6835386B2 · Gutierrez · 2004 [cited by applicant]
US 6927210B1 · Thompson et al. · 2005 [cited by applicant]
US 6936269B2 · Robinson · 2005 [cited by applicant]
US 7232844B2 · Hallahan · 2007 [cited by applicant]
US 7307043B2 · Schlatter et al. · 2007 [cited by applicant]
US 7381431B2 · Baker et al. · 2008 [cited by applicant]
US 7531188B2 · Jones · 2009 [cited by applicant]
US 7579017B2 · Murphy et al. · 2009 [cited by applicant]
US 7807190B2 · Kinglsey · 2010 [cited by applicant]
US 7829551B2 · Ansell · 2010 [cited by applicant]
US 7846463B2 · Johal · 2010 [cited by applicant]
US 7846464B2 · Darling · 2010 [cited by applicant]
US 7902256B2 · Ping · 2011 [cited by applicant]
US 7988985B2 · Bessette · 2011 [cited by applicant]
US 7994138B2 · Awada et al. · 2011 [cited by applicant]
US 8062676B2 · Besendorfer · 2011 [cited by applicant]
US 8119150B2 · Tamarkin et al. · 2012 [cited by applicant]
US 8142801B2 · Jones · 2012 [cited by applicant]
US 8231887B2 · Sims · 2012 [cited by applicant]
US 8563018B2 · Burke · 2013 [cited by applicant]
US 8574641B2 · Pesso · 2013 [cited by applicant]
US 8771718B2 · Scialdone et al. · 2014 [cited by applicant]
US 8877219B2 · Bessette · 2014 [cited by applicant]
US 8889731B2 · Gries et al. · 2014 [cited by applicant]
US 8927595B2 · Spring et al. · 2015 [cited by applicant]
US 8968757B2 · Man et al. · 2015 [cited by applicant]
US 9055745B2 · James-Meyer et al. · 2015 [cited by applicant]
US 9101143B2 · Shoham et al. · 2015 [cited by applicant]
US 9173403B2 · Rosentel et al. · 2015 [cited by applicant]
US 9326524B1 · Jack et al. · 2016 [cited by applicant]
US 9403995B2 · Agrawal et al. · 2016 [cited by applicant]
US 9468207B2 · Mateo Herrero · 2016 [cited by applicant]
US 9642373B2 · Anderson · 2017 [cited by applicant]
US 9955695B2 · Found · 2018 [cited by applicant]
US 9999227B2 · Manhas et al. · 2018 [cited by applicant]
US 10149481B2 · Bissinger et al. · 2018 [cited by applicant]
US 10206393B2 · Goldblum et al. · 2019 [cited by applicant]
US 10328112B2 · Hatten · 2019 [cited by applicant]
US 10499637B2 · Mehlhorn et al. · 2019 [cited by applicant]
US 20010009925A1 · Lambino · 2001 [cited by examiner]
US 20030194454A1 · Bessette et al. · 2003 [cited by applicant]
US 20040037904A1 · Hakansson · 2004 [cited by applicant]
US 20040191290A1 · Kelley · 2004 [cited by applicant]
US 20050112164A1 · Lewey · 2005 [cited by applicant]
US 20060165748A1 · Arimoto · 2006 [cited by applicant]
US 20060228387A1 · Scialdone · 2006 [cited by applicant]
US 20070190094A1 · Bessette · 2007 [cited by applicant]
US 20070264294A1 · Lance-Gomez et al. · 2007 [cited by applicant]
US 20070264297A1 · Scialdone · 2007 [cited by examiner]
US 20080095813A1 · Kiec · 2008 [cited by applicant]
US 20080193387A1 · De Wolff · 2008 [cited by applicant]
US 20100197786A1 · Elraz · 2010 [cited by applicant]
US 20100204277A1 · Bowles et al. · 2010 [cited by applicant]
US 20100254928A1 · Yamazaki et al. · 2010 [cited by applicant]
US 20120087987A1 · Man et al. · 2012 [cited by applicant]
US 20120093949A1 · Steinberg · 2012 [cited by applicant]
US 20120107428A1 · Schneidmiller et al. · 2012 [cited by applicant]
US 20120164081A1 · De Lame et al. · 2012 [cited by applicant]
US 20150133406A1 · Bedoukian · 2015 [cited by applicant]
US 20150201615A1 · Schmidt · 2015 [cited by applicant]
US 20150216182A1 · Brown · 2015 [cited by applicant]
US 20160214974A1 · Schaetzer et al. · 2016 [cited by applicant]
US 20170360825A1 · Salamone et al. · 2017 [cited by applicant]
US 20180035674A1 · Schmidt et al. · 2018 [cited by applicant]
US 20180168149A1 · Jones · 2018 [cited by applicant]
US 20180213773A1 · Bedoukian · 2018 [cited by applicant]
US 20180213774A1 · Bedoukian · 2018 [cited by applicant]
US 20190091133A1 · Hansen · 2019 [cited by applicant]
US 20190216086A1 · Harding · 2019 [cited by applicant]
US 20190230930A1 · Baba · 2019 [cited by applicant]
US 20190313636A1 · Milbocker et al. · 2019 [cited by applicant]
US 20200093123A1 · Bradbury et al. · 2020 [cited by applicant]
US 20230090260A1 · Mitlitski et al. · 2023 [cited by applicant]
US 20230099513A1 · Mitlitski et al. · 2023 [cited by applicant]
AU 676219 · 1994 [cited by applicant]
CN 1164322 · 1997 [cited by applicant]
CN 102626094 · 2012 [cited by applicant]
CN 104430580 · 2015 [cited by applicant]
CN 105724440 · 2016 [cited by applicant]
CN 108743946 · 2018 [cited by applicant]
EP 1435786 · 2004 [cited by applicant]
EP 1962587 · 2008 [cited by applicant]
EP 2081428 · 2009 [cited by applicant]
EP 2348832 · 2011 [cited by applicant]
EP 2470006 · 2012 [cited by applicant]
EP 3253206 · 2017 [cited by applicant]
EP 3457847 · 2019 [cited by applicant]
FR 2948261 · 2011 [cited by applicant]
JP 2002068917 · 2002 [cited by applicant]
JP 3405736 · 2003 [cited by applicant]
JP 4356006 · 2009 [cited by applicant]
JP 2012246273A · 2012 [cited by examiner]
JP 2020109078A · 2020 [cited by examiner]
KR 101034323 · 2011 [cited by applicant]
RO 128885B1 · 2017 [cited by examiner]
WO 9108670 · 1991 [cited by applicant]
WO 2007085899 · 2007 [cited by applicant]
WO 2007093298 · 2007 [cited by applicant]
WO 2008101131 · 2008 [cited by applicant]
WO 2008124882 · 2008 [cited by applicant]
WO 2010134060 · 2010 [cited by applicant]
WO 2012059943 · 2012 [cited by applicant]
WO 2017151549 · 2017 [cited by applicant]
WO 2018050211 · 2018 [cited by applicant]
WO 2019008116 · 2019 [cited by applicant]
WO 2019150152 · 2019 [cited by applicant]
The VRG Group Blog (https://www.vrg.org/blog/2012/09/24/glycerol-and-mono-and-diglyceride-updates-mostly-vegetable-derived/) (Year: 2012). [cited by examiner]
RO-128885-B1 translated doc (Year: 2017). [cited by examiner]
JP-2012246273-A translated doc (Year: 2012). [cited by examiner]
USDA (chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.ams.usda.gov/sites/default/files/media/Soaps%20H%20report%202015.pdf). retrieved on Jul. 1, 2024. (Year: 2015). [cited by examiner]
Of Independent Chemical (https://independentchemical.com/blogs/sodium-citrate%E2%80%99s-commercial-applications-20050.aspx). Retrieved on Jul. 1, 2024. May 3, 2019. (Year: 2019). [cited by examiner]
JP-2020109078-A translated doc Jul. 16, 2020. (Year: 2020). [cited by examiner]
Mitlitski, Vadim; Non-Final Office Action for U.S. Appl. No. 18/073,535, filed Dec. 1, 2022, mailed Dec. 26, 2023, 35 pgs. [cited by applicant]
Mitlitski, Vadim; Non-Final Office Action for U.S. Appl. No. 18/073,538, filed Dec. 1, 2022, mailed Dec. 27, 2023, 32 pgs. [cited by applicant]
Mitlitski, Vadim; Applicant-Initiated Interview Summary for U.S. Appl. No. 18/073,535, filed Dec. 1, 2022, mailed Nov. 5, 2024, 6 pgs. [cited by applicant]
Mitlitski, Vadim; Applicant-Initiated Interview Summary for U.S. Appl. No. 18/073,538, filed Dec. 1, 2022, mailed Nov. 5, 2024, 6 pgs. [cited by applicant]
Mitlitski, Vadim; Final Office Action for U.S. Appl. No. 18/073,535, filed Dec. 1, 2022, mailed Jul. 16, 2024, 23 pgs. [cited by applicant]
UL Prospector (https://www.ulprospector.com/en/na/PersonalCare/Detail/10811/330761/LEVENOL-HandB)., retrieved on Jun. 4, 2024. (Year: 2024). [cited by applicant]
Mitlitski, Vadim; Final Office Action for U.S. Appl. No. 18/073,538, filed Dec. 1, 2022, mailed Jul. 1, 2024, 14 pgs. [cited by applicant]
Mitlitski, Vadim; Notice of Allowance for U.S. Appl. No. 18/073,535, filed Dec. 1, 2022, mailed Mar. 31, 2025, 19 pgs. [cited by applicant]
Mitlitski, Vadim; Notice of Allowance for U.S. Appl. No. 18/073,538, filed Dec. 1, 2022, mailed Apr. 15, 2025, 23 pgs. [cited by applicant]